Posts tagged closely-held
Wendy Naimark joins Interface Biologics as VP of R&D

Closely-held Interface Biologics (IBI) has appointed Wendy Naimark as VP of research & development.

Wendy joins IBI after five years as senior director, clinical and preclinical sciences at 480 Medical, an early-stage drug delivery device company in the cardiovascular space. Previously, she spent 11 years at Boston Scientific in increasingly senior management and R&D roles in the areas of interventional cardiology, peripheral interventions, imaging, endosurgery, urology/women’s health and neurovascular.

Read More
AmorChem spins out CD36 technology into Mperia Therapeutics

Closely-held AmorChem has spun out Mperia Therapeutics, a start-up company focusing on a novel immunotherapy approach based on CD36 cell receptor drug-ligands.

All rights to the CD36 technology initially held by AmorChem have been transferred to Mperia, with a first Series A investment of $1-million. The capital injection will allow Mperia to pursue early-stage development of lead candidates for the treatment of dry age-related macular degeneration (AMD), a leading cause of blindness in seniors.

Read More
ASLAN Pharma in licensing pact with A*STAR

Closely-held ASLAN Pharmaceuticals has licensed a novel immuno-oncology antibody, targeting RON (Recepteur d’Origine Nantais), from Singapore’s Agency for Science, Technology and Research (A*STAR).

RON is a receptor tyrosine kinase, and an overexpression of RON leads to increased tumor metastasis. As a result, RON activation in tumour cells promotes aggressive disease. 

Read More
Marc Becker joins CRISPR Therapeutics as CFO

Closely-held CRISPR Therapeutics has appointed Marc Becker as CFO to further support the company’s efforts to develop game-changing drugs derived from its proprietary CRISPR-Cas9 gene-editing technology platform.

Mr. Becker is a seasoned executive who brings more than 20 years of experience in commercial, operational and corporate finance and a deep understanding of the global biopharmaceutical industry.

Read More